Open AccessStandard guidelines of care: Performing procedures in patients on or recently administered with isotretinoin
Author(s) -
Venkataram Mysore,
Omprakash Heggadahalli Mahadevappa,
Shyamanta Barua,
Imran Majid,
Vishalakshi Viswanath,
Ramesh M Bhat,
S Talwar,
T Salim,
Sanjeev Aurangabadkar,
Manas Chatterjee,
Anil Ganjoo
Publication year - 2017
Publication title -
journal of cutaneous and aesthetic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.44
H-Index - 13
eISSN - 0974-5157
pISSN - 0974-2077
DOI - 10.4103/jcas.jcas_110_17
Subject(s) - medicine , isotretinoin , dermabrasion , task force , discontinuation , surgery , dermatology , protocol (science) , hair removal , hypertrophic scars , acne , scars , alternative medicine , pathology , public administration , political science
Currently, the standard protocol regarding the performance of procedures on patients receiving or having recently received isotretinoin (13- cis -retinoic acid) states that the procedures should not be performed. The recommendations in standard books and drug insert require discontinuation of isotretinoin for 6 months before performing cosmetic procedures, including waxing, dermabrasion, chemical peels, laser procedures, or incisional and excisional cold-steel surgery. These recommendations have been followed for over two decades despite little evidence for the stated increased risk of scarring.